Clinical evaluation of sequentially scheduled cisplatin and VM26 in neuroblastoma: response and toxicity. Cancer 1981 Oct 15;48(8):1715-8
Date
10/15/1981Pubmed ID
7197189DOI
10.1002/1097-0142(19811015)48:8<1715::aid-cncr2820480805>3.0.co;2-yScopus ID
2-s2.0-0019415637 (requires institutional sign-in at Scopus site) 93 CitationsAbstract
Cis-dichlorodiammineplatinum (CDDP) and VM26, both of which have been proven efficient in treating neuroblastoma, were combined in a sequential schedule and administered to 22 children with disseminated neuroblastomas resistant to treatment with cyclophosphamide and doxorubicin (Adriamycin). During this same study, 14 children were prospectively evaluated for the effect of CDDP on magnesium metabolism and the effect of the induced hypomagnesemia on parathyroid function. Complete or partial tumor responses were achieved in six and nine cases. Respectively and were of prolonged duration (longer than six months) in eight of the 15 responding. It was also shown that CDDP-induced hypomagnesemia is the result of excessive renal loss and is severe enough to interfere with the normal parathormone response to hypocalcemia.
Author List
Hayes FA, Green AA, Casper J, Cornet J, Evans WEMESH terms used to index this publication - Major topics in bold
Bone MarrowChild
Child, Preschool
Cisplatin
Drug Administration Schedule
Drug Evaluation
Humans
Hypocalcemia
Magnesium
Mitotic Index
Neuroblastoma
Parathyroid Hormone
Podophyllotoxin
Prospective Studies
Teniposide
